News
The Impact of Science Policy Research
27 October 2010
Science, technology and innovation (STI) are gaining even greater importance with globalisation and international competition. The benefits STI provides, however, also carry risks and social costs.…
Access to Orphan Drugs in the EU
21 October 2010
Legislation in the EU provides incentives for the developmeng of drugs for rare diseases, known as orphan medicinal products (OMPs). At a recent conference, OHE’s Dr…
Biomedical and Health Research Spillovers in the UK
14 October 2010
Research spillovers exist when research by one organisation creates increased output for other organisations that operate in the same or other sector of the economy. Given…
New Antimicrobial Drugs: EU Policy Options
4 October 2010
Antimicrobial resistance to drugs is a growing global public health issue. The EU began a discussion in 2009 about which policies can best encourage the development…
Which English Hospital is Best at Hips?
29 September 2010
Earlier this month, the first set of data on post operative patient reported outcomes (PROMs) was published by the Department of Health (DH). For the first…
Costs and Bariatric Surgery in England
23 September 2010
Obesity is an increasing challenge in England, as elsewhere. OHE has completed a study that examines PCT practice and the cost savings that could accrue if…
OHE Consulting: Local and Global Expertise
14 September 2010
OHE Consulting makes the expertise of the team at the Office of Health Economics available to organisations in all sectors – public, private and voluntary. The…
Value Based Pricing in the UK
7 September 2010
Every country around the globe struggles with attaining an appropriate balance between providing affordable health care and ensuring access to medical advances. In a recent article…
Defining Benefit Through Willingness to Pay
24 August 2010
Since 2007, new medications may be paid for by the statutory health insurance funds (GKV) in Germany only if they are cost-effective. Willingness-to-pay analyses can be…